Sunzen Group Berhad (“Sunzen” or “the Group”) an established player in Malaysia’s health products, medical devices and services, and loan financing with a diversified portfolio, today announced its unaudited financial results for the third quarter ended 31 March 2026 (“Q3 FY2026”), recording revenue of RM23.97 million and profit before tax (“PBT”) of RM3.15 million.
The performance was mainly supported by stronger contribution from the loan financing segment, improved export sales of edible bird’s nest, and continued profitability from the Group’s diversified business base. For the cumulative nine months ended 31 March 2026 (“9M FY2026”), Sunzen registered revenue of RM73.89 million and PBT of RM13.48 million, representing a significant 137.3% increase in PBT from RM5.68 million in the corresponding period last year.
For Q3 FY2026, the Group’s revenue rose 52.8% year-on-year from RM15.69 million in the corresponding quarter last year, driven mainly by higher sales volume of food and beverages, increased export sales of edible bird’s nest, and improved interest income from loan financing. PBT increased 64.1% to RM3.15 million compared to RM1.92 million previously, mainly attributable to higher interest income from loan financing, which helped partially offset lower profit margins and higher operating expenses in the human health segment.
Quarter-on-quarter (“QoQ”), revenue declined 20.7% from RM30.24 million in Q2 FY2026, while PBT decreased 52.7% from RM6.65 million. The sequential moderation was mainly due to seasonal factors, as sales normalised following the seasonal peak in the preceding quarter. The softer QoQ earnings were also impacted by lower revenue from human health products and medical devices and services, higher marketing and distribution expenses, as well as lower bad debt recovery compared to the RM1.35 million recorded in the preceding quarter.
For 9M FY2026, the Group’s revenue increased 12.0% year-on-year to RM73.89 million from approximately RM66.00 million previously. The top-line improvement was primarily driven by higher sales volume of food and beverages, increased export sales of edible bird’s nest and improved interest income from the loan financing segment. PBT surged to RM13.48 million from RM5.68 million, supported by robust interest income, improved profitability from the human health segment, and bad debt recovery of RM1.35 million recognised during the current financial year.
The Human Health segment recorded revenue of RM17.28 million in Q3 FY2026, representing a strong 78.5% increase from RM9.68 million in the corresponding quarter last year. For 9M FY2026, the segment’s revenue increased 9.9% to RM53.09 million, supported by stronger demand for edible bird’s nest products. Despite the higher quarterly revenue, the segment recorded a loss before tax of RM0.56 million in Q3 FY2026, mainly due to lower profit margins and higher marketing expenses. On a cumulative basis, however, the segment turned profitable with PBT of RM0.44 million, compared to a loss before tax of RM0.82 million in the corresponding period last year.
The Medical Devices and Services segment registered revenue of RM1.87 million for the quarter, compared to RM2.48 million a year ago, mainly due to lower procurement from clinics and hospitals during the festive period. The segment recorded PBT of RM0.05 million for Q3 FY2026. For 9M FY2026, revenue stood at RM6.51 million compared to RM4.92 million in the corresponding six-month period from October 2024 previously, while PBT improved to RM0.95 million from RM0.78 million, reflecting continued contribution from ophthalmic-related products and services despite near-term procurement timing fluctuations.
The Loan Financing segment continued to anchor the Group’s earnings performance, with quarterly revenue increasing 36.8% year-on-year to RM4.83 million, driven by higher loan disbursements and sustained financing demand. PBT rose 41.7% to RM3.57 million from RM2.52 million previously. For 9M FY2026, the segment recorded revenue of RM14.29 million, up 42.9% year-on-year, while PBT increased 49.6% to RM10.80 million, supported by higher revenue from expanded loan disbursements and bad debt recovery of RM0.57 million recognised during the period.
Group Managing Director of Sunzen Group Berhad, Mr. Teo Yek Ming said, “Our latest quarterly performance reflects the benefit of having a diversified earnings base. While certain segments were affected by seasonality and softer procurement cycles, our loan financing business continued to deliver strong growth and provided a stable earnings anchor for the Group.”
He added, “We are encouraged by the recovery in edible bird’s nest sales and the year-to-date turnaround in our human health segment. Moving forward, our focus remains on strengthening margins, expanding distribution reach, and improving operational efficiency across our core businesses.”
Looking ahead, Sunzen remains cautiously optimistic on its prospects. The Group expects the Human Health segment to continue strengthening its distribution footprint, supported by engagement with selected chain retailers, participation in fast-moving consumer goods channels, trade fairs, promotional events, and growing online sales traction. These initiatives are expected to improve brand visibility and reduce the impact of seasonal demand fluctuations.
